JP2005511722A5 - - Google Patents

Download PDF

Info

Publication number
JP2005511722A5
JP2005511722A5 JP2003550791A JP2003550791A JP2005511722A5 JP 2005511722 A5 JP2005511722 A5 JP 2005511722A5 JP 2003550791 A JP2003550791 A JP 2003550791A JP 2003550791 A JP2003550791 A JP 2003550791A JP 2005511722 A5 JP2005511722 A5 JP 2005511722A5
Authority
JP
Japan
Prior art keywords
disease
pharmaceutical composition
composition according
active ingredient
dose
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2003550791A
Other languages
English (en)
Other versions
JP2005511722A6 (ja
JP2005511722A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2002/039289 external-priority patent/WO2003049742A1/en
Publication of JP2005511722A publication Critical patent/JP2005511722A/ja
Publication of JP2005511722A6 publication Critical patent/JP2005511722A6/ja
Publication of JP2005511722A5 publication Critical patent/JP2005511722A5/ja
Pending legal-status Critical Current

Links

Claims (13)

  1. 有効成分としてBIRB 796 BSを含有するサイトカイン介在性疾患治療用医薬組成物
  2. 有効成分の各投与量が、150mg未満である、請求項1に記載の医薬組成物
  3. 有効成分の各投与量が、4〜100mgである、請求項1に記載の医薬組成物
  4. 有効成分の各投与量が、4、5、15、30、45、60、75又は100mgである、請求項1に記載の医薬組成物
  5. サイトカイン介在性疾患が、煙の吸入により生じる肺の急性及び慢性炎症、子宮内膜症、ベーチェット病、ブドウ膜炎及び強直性脊椎炎、膵炎、ライム病、慢性関節リウマチ、炎症性腸疾患、敗血性ショック、変形性関節炎、クローン病、潰瘍性大腸炎、多発性硬化症、ギランバレー症候群、乾癬、移植片対宿主病、全身性エリテマトーデス、経皮的冠動脈形成術後の再狭窄、糖尿病、毒素性ショック症候群、アルツハイマー病、急性及び慢性の疼痛、接触性皮膚炎、アテローム性動脈硬化症、外傷性関節炎、糸球体腎炎、再潅流傷害、敗血症、骨吸収疾患、慢性閉塞性肺疾患、うっ血性心不全、喘息、脳卒中、心筋梗塞、温熱傷害、成人呼吸窮迫症候群(ARDS)、損傷に対する二次的他臓器傷害、急性炎症性コンポーネントを伴う皮膚病、急性化膿性髄膜炎、壊死性腸炎、及び血液透析、白血球交換療法又は顆粒球注入に関連する症候群から選ばれる、請求項1〜のいずれか1項に記載の医薬組成物
  6. 疾患が、慢性関節リウマチ、変形性関節炎、クローン病、乾癬、潰瘍性大腸炎、骨粗鬆症、慢性閉塞性肺疾患、経皮的冠動脈形成術後の再狭窄及びうっ血性心不全から選ばれる、請求項に記載の医薬組成物
  7. 疾患が、慢性関節リウマチ、変形性関節炎、クローン病及び乾癬から選ばれる、請求項に記載の医薬組成物
  8. 有効成分の各投与量が、30、50、60、70又は90mgである、請求項に記載の医薬組成物
  9. 疾患が、慢性関節リウマチ、クローン病及び乾癬から選ばれる、請求項に記載の医薬組成物
  10. 有効成分の各投与量が50又は70mgであり、疾患が慢性関節リウマチである、請求項に記載の医薬組成物
  11. 有効成分の各投与量が50、60、70又は90mgであり、疾患がクローン病である、請求項に記載の医薬組成物
  12. 有効成分の各投与量が30、50又は70mgであり、疾患が乾癬である、請求項に記載の医薬組成物
  13. サイトカイン介在性疾患治療用医薬組成物を製造するためのBIRB 796 BSの使用
JP2003550791A 2001-12-11 2002-12-06 Birb796bsの投与方法 Pending JP2005511722A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US33924901P 2001-12-11 2001-12-11
US60/339,249 2001-12-11
PCT/US2002/039289 WO2003049742A1 (en) 2001-12-11 2002-12-06 Method for administering birb 796 bs

Publications (3)

Publication Number Publication Date
JP2005511722A JP2005511722A (ja) 2005-04-28
JP2005511722A6 JP2005511722A6 (ja) 2005-08-04
JP2005511722A5 true JP2005511722A5 (ja) 2006-02-02

Family

ID=23328156

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2003550791A Pending JP2005511722A (ja) 2001-12-11 2002-12-06 Birb796bsの投与方法

Country Status (6)

Country Link
US (2) US20030118575A1 (ja)
EP (1) EP1455791A1 (ja)
JP (1) JP2005511722A (ja)
AU (1) AU2002366644A1 (ja)
CA (1) CA2465759A1 (ja)
WO (1) WO2003049742A1 (ja)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040110755A1 (en) * 2002-08-13 2004-06-10 Boehringer Ingelheim Pharmaceuticals, Inc. Combination therapy with p38 MAP kinase inhibitors and their pharmaceutical compositions
FR2846328B1 (fr) * 2002-10-23 2004-12-10 Servier Lab Nouveaux derives de l'imidazoline, leur procede de preparation et les compositions pharmaceutiques qui les contiennent.
RU2006108864A (ru) * 2003-08-22 2007-09-27 Берингер Ингельхайм Фармасьютиклз, Инк. (Us) Способы лечения хронического обструктивного заболевания легких (хозл) и легочной гипертензии
AU2004270733B2 (en) 2003-09-11 2011-05-19 Itherx Pharma, Inc. Cytokine inhibitors
WO2006062982A2 (en) 2004-12-07 2006-06-15 Locus Pharmaceuticals, Inc. Urea inhibitors of map kinases
US7612200B2 (en) 2004-12-07 2009-11-03 Locus Pharmaceuticals, Inc. Inhibitors of protein kinases
US7774275B2 (en) * 2005-02-28 2010-08-10 Searete Llc Payment options for virtual credit
US20060190282A1 (en) * 2005-02-04 2006-08-24 Jung Edward K Providing risk mitigation in a virtual world
US8512143B2 (en) * 2005-07-18 2013-08-20 The Invention Science Fund I, Llc Third party control over virtual world characters
US8566111B2 (en) * 2005-02-04 2013-10-22 The Invention Science Fund I, Llc Disposition of component virtual property rights
US20080092065A1 (en) * 2005-02-04 2008-04-17 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Third party control over virtual world characters
US20070118420A1 (en) * 2005-02-04 2007-05-24 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Context determinants in virtual world environment
US20080103951A1 (en) * 2005-02-04 2008-05-01 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Virtual credit in simulated environments
US20090099930A1 (en) * 2005-02-04 2009-04-16 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Participation profiles of virtual world players
US8556723B2 (en) * 2005-02-04 2013-10-15 The Invention Science Fund I. LLC Third party control over virtual world characters
US20070156509A1 (en) * 2005-02-04 2007-07-05 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Real-world incentives offered to virtual world participants
US8457991B2 (en) * 2005-02-04 2013-06-04 The Invention Science Fund I, Llc Virtual credit in simulated environments
US20090043683A1 (en) * 2005-02-04 2009-02-12 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Virtual world reversion rights
US7937314B2 (en) * 2005-10-21 2011-05-03 The Invention Science Fund I Disposition of component virtual property rights
US20070013691A1 (en) * 2005-07-18 2007-01-18 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Supervisory authority in virtual world environment
US7890419B2 (en) * 2005-02-04 2011-02-15 The Invention Science Fund I, Llc Virtual credit in simulated environments
US20090144148A1 (en) * 2005-02-04 2009-06-04 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Attribute enhancement in virtual world environments
US7720687B2 (en) 2005-10-03 2010-05-18 The Invention Science Fund I, Llc Virtual world property disposition after real-world occurrence
US8060829B2 (en) 2005-04-15 2011-11-15 The Invention Science Fund I, Llc Participation profiles of virtual world players
US20090138333A1 (en) * 2005-02-04 2009-05-28 Searete Llc, A Limited Liablity Of The State Of Delaware Follow-up contacts with virtual world participants
US7958047B2 (en) * 2005-02-04 2011-06-07 The Invention Science Fund I Virtual credit in simulated environments
US20070168214A1 (en) * 2005-03-30 2007-07-19 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Virtual credit with transferability
US20070198305A1 (en) * 2005-03-30 2007-08-23 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Virtual credit with transferability
US8271365B2 (en) * 2005-02-04 2012-09-18 The Invention Science Fund I, Llc Real-world profile data for making virtual world contacts
US20080270165A1 (en) * 2005-02-04 2008-10-30 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Virtual world property disposition after real-world occurrence
US8473382B2 (en) * 2006-02-28 2013-06-25 The Invention Science Fund I, Llc Virtual collateral for real-world obligations
US20080215434A1 (en) * 2005-02-04 2008-09-04 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Real world interaction with virtual world privileges
US20070078737A1 (en) * 2005-02-28 2007-04-05 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Financial ventures based on virtual credit
US20100016449A1 (en) * 2006-12-21 2010-01-21 Boehringer Ingelheim International Gmbh Formulations with Improved Bioavailability
EP3257862A1 (en) 2016-06-16 2017-12-20 ETH Zürich Fibronectin-binding peptides for use in tumor or fibrosis diagnosis and therapy
SG10202110259QA (en) 2017-10-05 2021-10-28 Fulcrum Therapeutics Inc Use of p38 inhibitors to reduce expression of dux4
US10342786B2 (en) 2017-10-05 2019-07-09 Fulcrum Therapeutics, Inc. P38 kinase inhibitors reduce DUX4 and downstream gene expression for the treatment of FSHD

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4105766A (en) * 1977-08-19 1978-08-08 Sterling Drug Inc. 4,5-Dihydro-5-oxopyrazolo[1,5-a]quinazoline-3-carboxylic acid derivatives
HU185294B (en) * 1980-12-29 1984-12-28 Chinoin Gyogyszer Es Vegyeszet Process for producing substituted urea derivatives
US5162360A (en) * 1991-06-24 1992-11-10 Warner-Lambert Company 2-heteroatom containing urea and thiourea ACAT inhibitors
MX9300141A (es) * 1992-01-13 1994-07-29 Smithkline Beecham Corp Compuestos de imidazol novedosos, procedimiento para su preparacion y composiciones farmaceuticas que lo contienen.
US5869043A (en) * 1993-09-17 1999-02-09 Smithkline Beecham Corporation Drug binding protein
US5783664A (en) * 1993-09-17 1998-07-21 Smithkline Beecham Corporation Cytokine suppressive anit-inflammatory drug binding proteins
ATE186551T1 (de) * 1993-09-17 1999-11-15 Smithkline Beecham Corp Medikamente bindendes protein
US5739143A (en) * 1995-06-07 1998-04-14 Smithkline Beecham Corporation Imidazole compounds and compositions
US5948885A (en) * 1996-05-20 1999-09-07 Signal Pharmaceuticals, Inc. Mitogen-activated protein kinase p38-2 and methods of use therefor
WO1997047618A1 (en) * 1996-06-10 1997-12-18 Merck & Co., Inc. Substituted imidazoles having cytokine inhibitory activity
US5851812A (en) * 1997-07-01 1998-12-22 Tularik Inc. IKK-β proteins, nucleic acids and methods
UA73492C2 (en) * 1999-01-19 2005-08-15 Aromatic heterocyclic compounds as antiinflammatory agents
WO2000050425A1 (en) * 1999-02-22 2000-08-31 Boehringer Ingelheim Pharmaceuticals, Inc. Polycyclo heterocyclic derivatives as antiinflammatory agents
US6565880B2 (en) * 2000-07-24 2003-05-20 Boehringer Ingelheim Pharmaceuticals, Inc. Oral dosage formulations of 1-(5-tert-butyl-2-p-tolyl-2H-pyrazol-3-yl)-3-[4-(2-morpholin-4-yl-ethoxy)-naphthalen-1-yl]-urea
WO2003015828A1 (en) * 2001-08-20 2003-02-27 Boehringer Ingelheim Pharmaceuticals, Inc. Parenteral formulations of 1-(5-tert-butyl-2-p-tolyl-2h-pryrazol-3-yl)-3-[4-(2-morpholin-4-yl-ethoxy)-naphthalen-1-yl]-urea and a cyclodextrin
JP2005506350A (ja) * 2001-10-18 2005-03-03 ベーリンガー インゲルハイム ファーマシューティカルズ インコーポレイテッド サイトカイン阻害薬としての1,4−二置換ベンゾ−縮合尿素化合物

Similar Documents

Publication Publication Date Title
JP2005511722A5 (ja)
JP2005531584A5 (ja)
JP2005523338A5 (ja)
JP2005529890A5 (ja)
JP2005506350A5 (ja)
ES2251360T3 (es) Compuestos heterociclicos aromaticos en calidad de agentes antiinflamatorios.
NZ591115A (en) Azaindazole compounds as ccr1 receptor antagonists
JP2008508303A5 (ja)
RU2007102576A (ru) Новые индаэолкарбоксамиды и их применение
HRP20110763T1 (hr) Makrolidni konjugati s protuupalnom aktivnošću
JP2009531292A5 (ja)
JP2004531571A5 (ja)
JP2007535586A5 (ja)
JP2009510051A5 (ja)
EP2079732A1 (en) 3- (1, 3-benz0di0x0l-5-yl) -6- (4-cyclopropylpiperazin-1-yl) -pyridazine, its salts and solvates and its use as histamine h3 receptor antagonist
CN106456639B (zh) Hiv逆转录酶抑制剂的前药
JP2009537596A (ja) 6−(4−シクロプロピルピペリジン−1−イル)−2’−メチル−[3,4’]−ビピリジン及びその医薬としての使用
JP2007529492A5 (ja)
JP2007518801A5 (ja)
JP2008533077A5 (ja)
JP2008516991A5 (ja)
Gothner et al. The use of double lumen cannula for veno-venous ECMO in trauma patients with ARDS
EP1523988A4 (en) COMPOSITION WITH RADIX CODONOPSIS PILOSULAE AND RADIX ASTRAGALI AND HEDYSARI, METHOD OF MANUFACTURING THEREFOR AND THEIR USE
NZ547523A (en) Novel tiotropium salts, methods for the production thereof, and pharmaceutical formulations containing the same
JP2008528639A5 (ja)